A startup called Acorai has developed a non-invasive heart failure monitoring technology that uses wireless sensors to track patients’ vital signs. The company has just closed a $4.5 million seed raise and plans to use the funding for clinical studies as it works towards FDA approval for clinical use.
Here are some key points from the article:
- Acorai’s technology involves wearing a small, non-invasive sensor on the chest that tracks heart rate, breathing rate, and other vital signs.
- The sensor sends data to a cloud-based platform where it is analyzed by AI algorithms to identify early warning signs of heart failure.
- The company has secured a $4.5 million seed raise led by Solardis Health Ventures, with participation from KHP Ventures, Carma Fund, and several other investors.
- Acorai plans to use the funding for clinical studies as it works towards FDA approval for clinical use.
- The startup is planning to commercialize its product in the US first, rather than in Europe, where healthcare regulation is more fragmented.
- Acorai has partnered with several high-profile organizations, including Mayo Clinic and Cedars-Sinai, which have invested in the company.
Overall, it seems that Acorai’s technology has significant potential for improving heart health outcomes, and the company’s recent funding round will help to support its efforts towards FDA approval.
